Dare Bioscience (NASDAQ:DARE) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Dare Bioscience (NASDAQ:DARE) to a hold rating in a report issued on Saturday morning.

Dare Bioscience Stock Performance

DARE stock opened at $2.20 on Friday. The company has a market capitalization of $19.87 million, a PE ratio of -1.03 and a beta of 1.11. Dare Bioscience has a one year low of $1.83 and a one year high of $9.19. The company’s 50 day moving average price is $2.55 and its two-hundred day moving average price is $2.83.

Dare Bioscience (NASDAQ:DARE) last issued its earnings results on Thursday, August 14th. The biotechnology company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.10. The firm had revenue of ($0.02) million during the quarter, compared to analysts’ expectations of $0.14 million. On average, research analysts predict that Dare Bioscience will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Dare Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after buying an additional 3,593 shares during the period. Renaissance Technologies LLC increased its stake in shares of Dare Bioscience by 6.7% in the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after buying an additional 4,300 shares during the period. AMH Equity Ltd increased its stake in shares of Dare Bioscience by 9.5% in the first quarter. AMH Equity Ltd now owns 164,302 shares of the biotechnology company’s stock worth $475,000 after buying an additional 14,302 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Dare Bioscience in the fourth quarter worth $52,000. 6.70% of the stock is owned by hedge funds and other institutional investors.

About Dare Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.